North America Plasma Fractionation Market, By Product Type (Immunoglobulins, Coagulation Factor Concentrates, Albumin, Protease Inhibitors and Other Products), Application (Neurology, Immunology, Hematology, Critical Care, Pulmonology, Hemato- Oncology, Rheumatology and Others), Processing Technology (Ion- Exchange Chromatography , Affinity Chromatography, Cryopreservation, Ultrafiltration and Microfiltration), Mode (Modern Plasma Fractionation and Traditional Plasma Fractionation), End User (Hospitals & Clinics, Clinical Research Laboratories Academic Institutions and Others), Distribution Channel (Direct Tenders, Third Party Distribution and Others) , Country (Germany, U.K., Italy, France, Spain, Switzerland, Netherlands, Russia, Turkey, and Rest of North America) Industry Trends and Forecast to 2028.
Market Analysis and Insights: North America Plasma Fractionation Market
North America plasma fractionation market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.7% in the forecast period of 2021 to 2028 and is expected to reach USD 20,855.60 million by 2028. High presence of number of plasma collection centres are helping in growing demand of the plasma fractionation market.
Plasma is a blood component that derives from whole blood by plasmapheresis and is used for various therapeutic and medical applications. Human plasma is s source of numerous different proteins. However, only few of these proteins are useful for producing therapeutic plasma products. The process of separation, extraction and purification of these proteins from the plasma is called fractionation process.
North America plasma fractionation market is growing with factors such as rise in respiratory diseases across the world, increase in aging population with blood-related ailments and increasing usage of immunoglobulins. Increase in rare diseases that require the use of plasma therapy or plasma derivatives also acts as a major factor for the growth of the market. Increasing investment in research and development has also given a boom to the North America plasma fractionation market.
However, the stringent government regulations regarding the plasma therapies are restraining the growth of plasma fractionation market. Additionally, the shortage of plasma proteins acts as a hindrance towards the growth of the market.
This plasma fractionation market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
North America Plasma Fractionation Market Scope and Market Size
North America plasma fractionation market is segmented into six notable segments which are based on the product type, application, processing technology, mode, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product type, the plasma fractionation market is segmented into immunoglobulins, coagulation factor concentrate, albumin, protease inhibitors and other products. In 2021, immunoglobulin has the largest market share owing to the effectiveness in treatment of the auto immune disorders due to the immunomodulatory functions
- On the basis of application, the plasma fractionation market is segmented into neurology, immunology, haematology, critical care, pulmonology, hemato- oncology, rheumatology and others. In 2021, immunology has the largest market share owing to the increase in the usage of plasma fractionated proteins in the treatment of various immunology related diseases.
- On the basis of processing technology, the plasma fractionation market is segmented into Ion- exchange chromatography, affinity chromatography, cryopreservation, ultrafiltration and microfiltration. In 2021, Ion- exchange chromatography has the largest market share owing to the high efficiency in the plasma fractionation process for extracting the plasma proteins
- On the basis of mode, the plasma fractionation market is segmented into modern plasma fraction and traditional plasma fractionation. In 2021, modern plasma fractions has the largest market share owing to the adopting the new and innovative technologies in order to reduce the impurities in the plasma fractionation process.
- On the basis of end user, the plasma fractionation market is segmented into Hospitals & clinics, clinical research laboratories academic institutions and others. In 2021, hospitals & clinics has the largest market share due increasing incidences of various diseases and emerging treatment techniques using plasma fractionated proteins.
- On the basis of distribution channel, the plasma fractionation market is segmented into direct tenders, third party distribution and others. 2021, direct tenders have the largest market share owing to the increase in the revenue through the direct sales by reducing the third party commission and by gathering consumer feedback.
North America Plasma Fractionation Market: Country Level Analysis
North America plasma fractionation market is analysed and market size information is provided by country, product type, application, processing technology, mode, end user and distribution channel as referenced above.
The countries covered in the North America plasma fractionation market report are U.S., Canada and Mexico.
U.S. is dominating in the North America plasma fractionation market with the highest CAGR as the geriatric population and immune deficiency diseases are rising in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Rising Demand of Plasma Fractionation
North America plasma fractionation market also provides you with detailed market analysis for every country growth in industry with sales, components sales, impact of technological development in plasma fractionation and changes in regulatory scenarios with their support for the plasma fractionation product market. The data is available for historic period 2010-2019.
Competitive Landscape and North America Plasma Fractionation Market Share Analysis
North America plasma fractionation market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, India presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to North America plasma fractionation market.
Some of the major players operating in the plasma fractionation market are Grifols, S.A., Takeda Pharmaceutical Company Limited, Octapharma AG, CSL Plasma, LFB SA, Green Cross Corp., Baxter, Bio Products Laboratory Ltd., Novasep Holding SAS, Pall Corporation, Bharat Serums and Vaccines Limited (BSV), Kedrion S.p.A, Sanquin, Biotest AG, Merck KGaA, ADMA Biologics, Inc., Boccard, Intas Pharmaceuticals Ltd., Japan Blood Products Organization and CENTURION Ilaç Sanayi ve Ticaret A.S. among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many product launches are also initiated by the companies worldwide which are also accelerating the growth of North America plasma fractionation market.
For instance,
- In April 2020, Grifols launched 3- ml vial for Hyper RAB which is rabies immune globulin in the plasma fractionation market to help in the treatment of rabies cases across the world.
Collaboration, joint ventures and other strategies by the market players is enhancing the company footprints in the Plasma Fractionation market which also provides the benefit for organisation in its growth pace.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA PLASMA FRACTIONATION MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET APPLICATION COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PRODUCTION FACILITIES FOR BLOOD PLASMA:
4.2 SUPPLIERS OF PROCESS LINES FOR PLASMA FRACTIONATION
4.2.1 RAW MATERIAL PROCUREMENT
4.2.2 MANUFACTURING
4.2.3 MARKETING & DISTRIBUTION
4.2.4 END-USERS
5 NORTH AMERICA PLASMA FRACTIONATION MARKET: REGULATORY
5.1 THE U.S.
5.2 INDIA
5.3 EUROPE
5.4 BRAZIL
5.5 SOUTH AFRICA
6 MARKET OVERVIEW
6.1 3.1 DRIVERS
6.1.1 3.1.1 INCREASE IN RARE DISEASES THAT REQUIRES USE OF PLASMA THERAPY OR PLASMA DERIVATIVE
6.1.2 RISE IN RESPIRATORY DISEASES ACROSS THE WORLD
6.1.3 INCREASE IN AGING POPULATION WITH BLOOD-RELATED AILMENTS
6.1.4 INCREASE USAGE OF IMMUNOGLOBULIN
6.2 RESTRAINTS
6.2.1 GROWING USAGE OF RECOMBINANT PROTEIN PRODUCTS
6.2.2 STRINGENT GOVERNMENT REGULATIONS REGARDING PLASMA THERAPY
6.2.3 RISK OF QUALITY AND SAFETY
6.3 OPPORTUNITIES
6.3.1 INCREASE IN PLASMA COLLECTION CENTRES
6.3.2 UNHEALTHY LIFESTYLE POSSESS SERIOUS INFLAMMATION RISK
6.3.3 ADVANCEMENT IN TECHNOLOGIES
6.4 CHALLENGES
6.4.1 SHORTAGE OF PLASMA PROTEINS
6.4.2 HIGH COST OF PLASMA THERAPY
7 IMPACT OF COVID-19 ON THE NORTH AMERICA PLASMA FRACTIONATION MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY CHAIN
7.4 STRATEGIC DECISIONS FOR MANUFACTURERS
7.5 CONCLUSION
8 NORTH AMERICA PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 IMMUNOGLOBULINS
8.2.1 INTRAVENOUS IMMUNOGLOBULINS
8.2.2 SUBCUTANEOUS IMMUNOGLOBULINS
8.2.3 OTHER IMMUNOGLOBULINS
8.3 COAGULATION FACTOR CONCENTRATES
8.3.1 FACTOR IX
8.3.2 FACTOR VIII
8.3.3 FIBRINOGEN CONCENTRATES
8.3.4 PROTHROMBIN COMPLEX CONCENTRATE
8.3.5 VON WILLEBRAND FACTOR
8.3.6 FACTOR XIII
8.4 ALBUMIN
8.5 PROTEASE INHIBITORS
8.6 OTHER PRODUCTS
9 NORTH AMERICA PLASMA FRACTIONATION MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 IMMUNOLOGY
9.3 HAEMATOLOGY
9.4 CRITICAL CARE
9.5 NEUROLOGY
9.6 PULMONOLOGY
9.7 HAEMATO-ONCOLOGY
9.8 RHEUMATOLOGY
9.9 OTHER APPLICATION
10 NORTH AMERICA PLASMA FRACTIONATION MARKET, BY PROCESSING TECHNOLOGY
10.1 OVERVIEW
10.2 ION-EXCHANGE CHROMATOGRAPHY
10.3 AFFINITY CHROMATOGRAPHY
10.4 ULTRAFILTRATION
10.5 MICROFILTRATION
10.6 CRYOPRECIPITATION
11 NORTH AMERICA PLASMA FRACTIONATION MARKET, BY MODE
11.1 OVERVIEW
11.2 MODERN PLASMA FRACTIONATION
11.3 TRADITIONAL PLASMA FRACTIONATION
12 NORTH AMERICA PLASMA FRACTIONATION MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS & CLINICS
12.3 CLINICAL RESEARCH LABORATORIES
12.4 ACADEMIC INSTITUTES
12.5 OTHERS
13 NORTH AMERICA PLASMA FRACTIONATION MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDERS
13.3 THIRD PARTY DISTRIBUTION
13.4 OTHERS
14 NORTH AMERICA PLASMA FRACTIONATION MARKET, BY REGION
14.1 NORTH AMERICA
14.1.1 U.S.
14.1.2 CANADA
14.1.3 MEXICO
15 NORTH AMERICA PLASMA FRACTIONATION MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 CSL PLASMA
17.1.1 COMPANY SNAPSHOT
17.1.2 COMPANY SHARE ANALYSIS
17.1.3 PRODUCT PORTFOLIO
17.1.4 RECENT DEVELOPMENTS
17.2 GRIFOLS, S.A.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 OCTAPHARMA AG
17.3.1 COMPANY SNAPSHOT
17.3.2 COMPANY SHARE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 RECENT DEVELOPMENTS
17.4 KENDRION S.P.A
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS
17.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENTS
17.6 BAXTER
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 ADMA BIOLOGICS INC.
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 BHARAT SERUMS AND VACCINES LIMITED (BSV)
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENT
17.9 BIO PRODUCTS LABORATORY LTD.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 BIOTEST AG
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENTS
17.11 BOCCARD
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENT
17.12 CENTURION İLAÇ SANAYI VE TICARET A.Ş.
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.13 CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENTS
17.14 GREEN CROSS CORP.
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENTS
17.15 INTAS PHARMACEUTICAL LTD.
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 JAPAN BLOOD PRODUCTS ORGANIZATION
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENT
17.17 KABAFUSION
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENTS
17.18 LFB SA
17.18.1 COMPANY SNAPSHOT
17.18.2 PRODUCT PORTFOLIO
17.18.3 RECENT DEVELOPMENTS
17.19 MERCK KGAA
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENT
17.2 NOVASEP HOLDING SAS
17.20.1 COMPANY SNAPSHOT
17.20.2 PRODUCT PORTFOLIO
17.20.3 RECENT DEVELOPMENTS
17.21 PALL CORPORATION
17.21.1 COMPANY SNAPSHOT
17.21.2 PRODUCT PORTFOLIO
17.21.3 RECENT DEVELOPMENT
17.22 SANQUIN
17.22.1 COMPANY SNAPSHOT
17.22.2 REVENUE ANALYSIS
17.22.3 PRODUCT PORTFOLIO
17.22.4 RECENT DEVELOPMENT
17.23 SHANGHAI RAAS
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENT
17.24 SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO., LTD
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENTS
17.25 SK PLASMA
17.25.1 COMPANY SNAPSHOT
17.25.2 PRODUCT PORTFOLIO
17.25.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 2 NORTH AMERICA IMMUNOGLOBULINS IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 3 NORTH AMERICA IMMUNOGLOBULINS IN PLASMA FRACTIONATION MARKET, PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA COAGULATION FACTOR CONCENTRATES IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA COAGULATION FACTOR CONCENTRATES IN PLASMA FRACTIONATION MARKET, PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA ALBUMIN IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA PROTEASE INHIBITORS IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA OTHER PRODUCTS IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA PLASMA FRACTIONATION MARKET, APPLICATION, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA IMMUNOLOGY IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA HAEMATOLOGY IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA CRITICAL CARE IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA NEUROLOGY IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA PULMONOLOGY IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA HAEMATO-ONCOLOGY IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA RHEUMATOLOGY IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA OTHER APPLICATION IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA PLASMA FRACTIONATION MARKET, PROCESSING TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA ION-EXCHANGE CHROMATOGRAPHY IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA AFFINITY CHROMATOGRAPHY IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA ULTRAFILTRATION IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA MICROFILTRATION IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA CRYOPRECIPITATION IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA PLASMA FRACTIONATION MARKET, MODE, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA MODERN PLASMA FRACTIONATION IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA TRADITIONAL PLASMA FRACTIONATION IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA PLASMA FRACTIONATION MARKET, END USER, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA HOSPITALS & CLINICS IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA CLINICAL RESEARCH LABORATORIES IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA ACADEMIC INSTITUTES IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA OTHERS IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA PLASMA FRACTIONATION MARKET, DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA DIRECT TENDERS IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA THIRD PARTY DISTRIBUTION IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 NORTH AMERICA OTHERS IN PLASMA FRACTIONATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA PLASMA FRACTIONATION MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 37 NORTH AMERICA PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 38 NORTH AMERICA IMMUNOGLOBULINS IN PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA COAGULATION FACTOR CONCENTRATES IN PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 40 NORTH AMERICA PLASMA FRACTIONATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 41 NORTH AMERICA PLASMA FRACTIONATION MARKET, BY PROCESSING TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 42 NORTH AMERICA PLASMA FRACTIONATION MARKET, BY MODE, 2019-2028 (USD MILLION)
TABLE 43 NORTH AMERICA PLASMA FRACTIONATION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 44 NORTH AMERICA PLASMA FRACTIONATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 45 U.S. PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 46 U.S. IMMUNOGLOBULINS IN PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 47 U.S. COAGULATION FACTOR CONCENTRATES IN PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 48 U.S. PLASMA FRACTIONATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 49 U.S. PLASMA FRACTIONATION MARKET, BY PROCESSING TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 50 U.S. PLASMA FRACTIONATION MARKET, BY MODE, 2019-2028 (USD MILLION)
TABLE 51 U.S. PLASMA FRACTIONATION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 52 U.S. PLASMA FRACTIONATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 53 CANADA PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 54 CANADA IMMUNOGLOBULINS IN PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 55 CANADA COAGULATION FACTOR CONCENTRATES IN PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 56 CANADA PLASMA FRACTIONATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 57 CANADA PLASMA FRACTIONATION MARKET, BY PROCESSING TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 58 CANADA PLASMA FRACTIONATION MARKET, BY MODE, 2019-2028 (USD MILLION)
TABLE 59 CANADA PLASMA FRACTIONATION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 60 CANADA PLASMA FRACTIONATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 61 MEXICO PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 62 MEXICO IMMUNOGLOBULINS IN PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 63 MEXICO COAGULATION FACTOR CONCENTRATES IN PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 64 MEXICO PLASMA FRACTIONATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 65 MEXICO PLASMA FRACTIONATION MARKET, BY PROCESSING TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 66 MEXICO PLASMA FRACTIONATION MARKET, BY MODE, 2019-2028 (USD MILLION)
TABLE 67 MEXICO PLASMA FRACTIONATION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 68 MEXICO PLASMA FRACTIONATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA PLASMA FRACTIONATION MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA PLASMA FRACTIONATION MARKET : DATA TRIANGULATION
FIGURE 3 NORTH AMERICA PLASMA FRACTIONATION MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA PLASMA FRACTIONATION MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA PLASMA FRACTIONATION MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA PLASMA FRACTIONATION MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA PLASMA FRACTIONATION MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA PLASMA FRACTIONATION MARKET : VENDOR SHARE ANALYSIS
FIGURE 9 NORTH AMERICA PLASMA FRACTIONATION MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 10 NORTH AMERICA PLASMA FRACTIONATION MARKET: SEGMENTATION
FIGURE 11 INCREASE IN RARE DISEASES THAT REQUIRES USE OF PLASMA THERAPY OR PLASMA DERIVATIVE IS EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA PLASMA FRACTIONATION MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 IMMUNOGLOBULINS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA PLASMA FRACTIONATION MARKET IN 2021 & 2028
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA PLASMA FRACTIONATION MARKET
FIGURE 14 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY PRODUCT TYPE, 2020
FIGURE 15 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY PRODUCT TYPE, 2020-2028 (USD MILLION)
FIGURE 16 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY PRODUCT TYPE, CAGR (2020-2028)
FIGURE 17 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY APPLICATION, 2020
FIGURE 19 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY APPLICATION, 2020-2028 (USD MILLION)
FIGURE 20 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY APPLICATION, CAGR (2020-2028)
FIGURE 21 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 22 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY PROCESSING TECHNOLOGY, 2020
FIGURE 23 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY PROCESSING TECHNOLOGY, 2020-2028 (USD MILLION)
FIGURE 24 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY PROCESSING TECHNOLOGY, CAGR (2020-2028)
FIGURE 25 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY PROCESSING TECHNOLOGY, LIFELINE CURVE
FIGURE 26 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY MODE, 2020
FIGURE 27 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY MODE, 2020-2028 (USD MILLION)
FIGURE 28 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY MODE, CAGR (2020-2028)
FIGURE 29 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY MODE, LIFELINE CURVE
FIGURE 30 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY END USER, 2020
FIGURE 31 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 32 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY END USER, CAGR (2020-2028)
FIGURE 33 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 35 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 36 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)
FIGURE 37 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 NORTH AMERICA PLASMA FRACTIONATION MARKET: SNAPSHOT (2020)
FIGURE 39 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY COUNTRY (2020)
FIGURE 40 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY COUNTRY (2021 & 2028)
FIGURE 41 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY COUNTRY (2020 & 2028)
FIGURE 42 NORTH AMERICA PLASMA FRACTIONATION MARKET: BY PRODUCT TYPE (2021 & 2028)
FIGURE 43 NORTH AMERICA PLASMA FRACTIONATION MARKET: COMPANY SHARE 2020 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.